APA (7th ed.) Citation

Kumar, D. P., Caffrey, R., Marioneaux, J., Santhekadur, P. K., Bhat, M., Alonso, C., . . . Sanyal, A. J. (2020). The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. Scientific Reports, 10(1), 1. https://doi.org/10.1038/s41598-020-66458-z

Chicago Style (17th ed.) Citation

Kumar, Divya P., et al. "The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease." Scientific Reports 10, no. 1 (2020): 1. https://doi.org/10.1038/s41598-020-66458-z.

MLA (9th ed.) Citation

Kumar, Divya P., et al. "The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease." Scientific Reports, vol. 10, no. 1, 2020, p. 1, https://doi.org/10.1038/s41598-020-66458-z.